Annovis Bio Secures $3.4 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies

Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer's and Parkinson's, has entered definitive agreements for a registered direct offering of 1,670,732 shares of common stock at $2.05 per share. The $3.4 million offering, which reflects the company's October 24 closing price, represents a significant capital infusion for the clinical-stage biopharmaceutical company. The transaction was led by H.C. Wainwright & Co. as exclusive placement agent, demonstrating institutional confidence in Annovis Bio's development pipeline and strategic direction.

The offering includes participation from key company leadership, with Chairman Michael Hoffman and CEO Dr. Maria Maccecchini both participating in the financing round. This insider participation signals strong conviction in the company's prospects and commitment to advancing its neurodegenerative disease programs. The closing of the offering is expected on or about October 28, 2025, with proceeds earmarked for working capital and general corporate purposes. This funding comes at a critical time for the company as it advances its clinical programs targeting Alzheimer's disease and Parkinson's disease, two of the most challenging neurodegenerative conditions affecting millions worldwide.

The capital raise provides Annovis Bio with additional resources to support its clinical development activities and operational needs. The company's focus on developing innovative therapies that address neurodegeneration in diseases such as AD and PD positions it in a therapeutic area with significant unmet medical needs and substantial market potential. For additional information about the company and its development programs, investors can visit https://www.annovisbio.com. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.

This financing represents an important milestone for Annovis Bio as it continues to advance its pipeline of neurodegenerative disease treatments. The successful completion of this offering provides the company with strengthened financial resources to pursue its clinical objectives and maintain momentum in its development programs. The participation of both institutional investors and company leadership in the offering underscores the collective belief in the company's potential to make meaningful advances in treating debilitating neurodegenerative conditions that affect growing patient populations globally.